HPV Vaccination and Testing Guidelines for Adult Males with Genital Warts

Vaccination Recommendations

The Advisory Committee on Immunization Practices (ACIP) recommends routine HPV vaccination with quadrivalent (4vHPV) or nonavalent (9vHPV) vaccine for males aged 13‑21 years (strong recommendation). 1
For males aged 22‑26 years, ACIP issues a permissive recommendation allowing vaccination (optional but permissible). 1
ACIP recommends routine vaccination (strong recommendation) for men who have sex with men (MSM) or HIV‑positive men aged 22‑26 years. 1
The presence of genital warts does not contraindicate HPV vaccination and should not delay vaccine administration; CDC advises vaccinating irrespective of prior or current genital warts. (strong recommendation) 1

For males, either the quadrivalent (4vHPV) or nonavalent (9vHPV) vaccine should be used; both protect against HPV types 6, 11, 16, and 18 (plus additional oncogenic types in 9vHPV). (strong recommendation) 1
The bivalent (2vHPV) vaccine is not recommended for males because it does not protect against HPV types 6 and 11, which cause ~90 % of genital warts. (strong recommendation) 3

Genital warts are most commonly caused by HPV types 6 and 11. (epidemiologic fact) 3
HPV vaccination provides no therapeutic benefit for HPV types already present in the patient but does protect against other vaccine‑covered types (e.g., oncogenic types 16 and 18). (moderate evidence) 5
Men with warts caused by HPV 6/11 remain susceptible to oncogenic HPV 16/18, which are responsible for the majority of HPV‑related cancers. (moderate evidence) 1

The CDC states that routine HPV testing should not be performed to screen asymptomatic men, male partners of HPV‑positive women, or men with visible genital warts. (strong recommendation) 3
No clinically validated HPV test exists for use in men; existing FDA‑cleared tests are approved only for cervical specimens. (moderate evidence) 6
HPV testing does not determine eligibility for vaccination and provides no clinical benefit for low‑risk types 6/11. (moderate evidence) 6

Genital warts can be transmitted even when no visible lesions are present. (strong evidence) 3
Transmission may continue after warts have been treated. (strong evidence) 3
Condoms reduce but do not eliminate HPV transmission because the virus can infect uncovered genital skin. (strong evidence) 3

Patients should inform current sexual partners of a genital‑wart diagnosis. (strong evidence) 3
Both partners should be screened for other sexually transmitted infections when one partner has genital warts. (strong evidence) 3

Approximately 20‑30 % of untreated genital warts resolve spontaneously within three months; the remainder may persist or enlarge. (moderate evidence) 7
Recurrence of genital warts is common, especially within the first three months after treatment. (moderate evidence) 3
Genital warts are not life‑threatening and rarely progress to cancer. (strong evidence) 3

Do not postpone HPV vaccination while awaiting wart treatment or clearance. (strong recommendation) 1
Do not order HPV testing in male patients, as it lacks clinical utility and validation. (strong recommendation) 3
Do not convey that condoms provide complete protection against HPV transmission. (strong recommendation) 3
Do not assume that asymptomatic periods indicate non‑infectiousness; individuals can transmit HPV without visible lesions. (strong recommendation) 3
Do not withhold vaccination from MSM or HIV‑positive men aged 22‑26 years; they have a routine (not permissive) recommendation. (strong recommendation) 1